LAMBERTUCCI, Catia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.612
EU - Europa 6.927
AS - Asia 5.135
SA - Sud America 708
AF - Africa 235
Continente sconosciuto - Info sul continente non disponibili 33
OC - Oceania 12
Totale 26.662
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.177
CN - Cina 2.063
SG - Singapore 1.570
RU - Federazione Russa 1.535
PL - Polonia 1.311
IT - Italia 1.136
DE - Germania 687
BR - Brasile 596
GB - Regno Unito 505
HK - Hong Kong 407
FR - Francia 404
UA - Ucraina 394
CA - Canada 368
VN - Vietnam 367
SE - Svezia 348
FI - Finlandia 257
KR - Corea 183
ZA - Sudafrica 166
TR - Turchia 148
IE - Irlanda 98
IN - India 87
JP - Giappone 84
MX - Messico 52
NL - Olanda 46
AR - Argentina 39
BE - Belgio 36
EU - Europa 33
BD - Bangladesh 31
ES - Italia 29
AT - Austria 25
CZ - Repubblica Ceca 25
IQ - Iraq 19
IR - Iran 19
EC - Ecuador 18
UZ - Uzbekistan 16
AE - Emirati Arabi Uniti 15
ID - Indonesia 14
KE - Kenya 14
LT - Lituania 14
PK - Pakistan 14
VE - Venezuela 13
CO - Colombia 12
RO - Romania 12
TW - Taiwan 12
IL - Israele 11
PY - Paraguay 11
SA - Arabia Saudita 11
CH - Svizzera 10
AU - Australia 9
AZ - Azerbaigian 9
DZ - Algeria 9
JO - Giordania 9
EG - Egitto 8
MA - Marocco 8
RS - Serbia 8
CL - Cile 7
PE - Perù 7
PH - Filippine 7
TN - Tunisia 7
AM - Armenia 5
BG - Bulgaria 5
CI - Costa d'Avorio 5
DK - Danimarca 5
ET - Etiopia 5
GR - Grecia 5
LB - Libano 5
NP - Nepal 5
AL - Albania 4
PA - Panama 4
BO - Bolivia 3
EE - Estonia 3
HR - Croazia 3
HU - Ungheria 3
KH - Cambogia 3
LV - Lettonia 3
MY - Malesia 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
BY - Bielorussia 2
CM - Camerun 2
GE - Georgia 2
JM - Giamaica 2
KW - Kuwait 2
KZ - Kazakistan 2
LU - Lussemburgo 2
NG - Nigeria 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
OM - Oman 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SY - Repubblica araba siriana 2
UY - Uruguay 2
BA - Bosnia-Erzegovina 1
BT - Bhutan 1
CR - Costa Rica 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GA - Gabon 1
Totale 26.643
Salva come PNG Salva come JPEG
Città #
Fairfield 1.293
Ashburn 1.151
Warsaw 1.141
Woodbridge 1.112
Jacksonville 961
Singapore 796
Chandler 762
Houston 701
San Jose 625
Seattle 577
Wilmington 518
Ann Arbor 481
Cambridge 440
Boardman 416
Hong Kong 387
Beijing 336
Nanjing 318
Dallas 257
Toronto 241
Camerino 220
The Dalles 203
Los Angeles 188
Seoul 155
Kraków 152
Johannesburg 151
New York 146
San Mateo 143
Columbus 141
Tongling 140
Dearborn 137
Lawrence 133
Princeton 133
Helsinki 129
Istanbul 121
Lauterbourg 113
Ho Chi Minh City 112
Düsseldorf 108
Ogden 108
Moscow 106
Nanchang 102
Dublin 97
London 96
Buffalo 91
Council Bluffs 89
Hanoi 88
Lachine 83
Shanghai 83
Chicago 73
Guangzhou 69
São Paulo 69
Frankfurt am Main 67
Tokyo 67
Shenyang 66
San Diego 63
Kunming 62
Santa Clara 62
Milan 59
Munich 59
Tianjin 56
Edinburgh 44
Jiaxing 43
Hebei 42
Orem 41
Centro 39
Brussels 35
Rome 34
Atlanta 30
Ningbo 30
Changsha 28
Jinan 28
Manchester 28
Stockholm 28
Denver 27
Phoenix 27
Chennai 26
Trieste 26
Hangzhou 25
Poplar 24
Verona 24
Wuhan 24
Brooklyn 23
Dong Ket 23
Montreal 23
San Francisco 23
Hefei 22
Norwalk 22
Boston 21
Mexico City 21
Falls Church 20
Orange 20
Turku 20
Ascoli Piceno 19
Bremen 19
Jinhua 19
Philadelphia 19
Redwood City 19
Salt Lake City 19
Rio de Janeiro 18
Tampa 18
Zhengzhou 18
Totale 17.912
Salva come PNG Salva come JPEG
Nome #
A2AR agonists/A3R antagonists: design, synthesis, and biological evaluation of new ligands with dual activity 437
The Length and Flexibility of the 2-Substituent of 9-Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human A2A Adenosine Receptor 402
Overview on Radiolabel-Free in Vitro Assays for GPCRs 397
Pharmacological characterization of the GPR17 receptor dual profile 379
GPR17 receptor modulators and their therapeutic implications: review of recent patents 373
The G Protein-Coupled Receptor GPR17: Overview and Update 366
2′,3′-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 358
2’,3’-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 348
Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications 304
Adenine based acyclic-nucleotides as novel P2X3 receptor ligands 290
8-(2-Furyl)adenine derivatives as A2A adenosine receptor ligands 286
Neuroprotective potential of adenosine A1 receptor partial agonists in experimental models of cerebral ischemia 280
Neuropeptide S Receptor: recent updates on non-peptide antagonist discovery 271
Simulation and Comparative Analysis of Different Binding Modes of Non-nucleoside Agonists at the A2A Adenosine Receptor 265
Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists 263
Investigation on 2′,3′-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists 263
Levels of polychlorinated biphenyls in fish and shellfish from the Adriatic Sea 255
Biomarkers Mapping in a Neuropathic Pain Mice Model with Sciatic Nerve Chronic Constriction Injury (CCI). 251
Approaches for designing and discovering purinergic drugs for gastrointestinal diseases 247
A taxane epoxide from taxus wallichiana 246
Adenine and deazaadenine nucleoside and deoxynucleoside analogues: inhibition of viral replication of sheep MVV (in vitro model for HIV) and bovine BHV-1 246
9-ethyladenine derivatives as adenosine receptor antagonists: 2- and 8-substitution results in distinct selectivities 245
3'-Deoxyribofuranose derivatives of 1-deaza and 3-deaza adenosine and their activity as adenosine deaminase inhibitors 244
Ex-vivo absorption study of lysine R-lipoate salt, a new pharmaceutical form of R-ALA 244
Antiproliferative Evaluation of Isofuranodiene on Breast and Prostate Cancer Cell Lines 241
A(2A) adenosine receptor agonists reduce both high-palatability and low-palatability food intake in female rats 240
Biomarkers mapping of neuropathic pain in a nerve chronic constriction injury mice model 236
Human cytidine deaminase: understanding the catalytic mechanism 235
New substituted 9-propyladenine derivatives as A2Aadenosine receptor antagonists 233
Design, synthesis, and biological evaluation of new mitonafide derivatives as potential antitumor drugs 231
Synthesis and evaluation of hexitol nucleoside congeners as ambiguous nucleosides 230
Innovative functional cAMP assay for studying G protein-coupled receptors: application to the pharmacological characterization of GPR17 230
8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A(2A) and A(2B) receptors ligands 230
Purinergic P2X receptors: Structural models and analysis of ligand-target interaction 227
Purine and deazapurine nucleosides: synthetic approaches, molecular modeling and biological activity 226
“Third Joint Italian-German Purine Club Meeting - Purinergic Receptors: New Frontiers for Novel Therapies” 226
Adenosine deaminase: Functional implications and different classes of inhibitors 223
New sensible method to quantize the intestinal absorption of receptor ligands 222
Non-Nucleoside Agonists of the Adenosine Receptors: An Overview 221
2- And 8- alkynyladenosines: conformational studies and docking to human adenosine A(3) receptor can explain their different biological behavior 220
A(2A) Adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists 219
Molecular modeling studies on the human neuropeptide S receptor and its antagonists. 218
Evidence for the existence of a specific G protein-coupled receptor activated by guanosine 216
Molecular modeling study on potent and selective adenosine A3 receptor agonists. 214
Antiviral properties of deazaadenine nucleoside derivatives 214
Adenosine A(2A) receptor antagonists: new 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease 210
Synthesis of a conformationally restricted analogue of paclitaxel 205
Comparison and optimization of transient transfection methods at human astrocytoma cell line 1321N1 204
Adenosine receptor modeling: what does the A2A crystal structure tell us? 203
Synthesis and NMR-Driven Conformational Analysis of Taxol Analogues Conformationally Constrained on the C13 Side Chain 203
Structure-activity relationships of adenine and deazaadenine derivatives as ligands for adenine receptors, a new purinergic receptor family 203
Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: Insight into the receptor activation switch 203
2- And 8-alkynyl-9-ethyladenines: Synthesis and biological activity at human and rat adenosines receptors 203
Fragment optimization for GPCRs by molecular dynamics free energy calculations: Probing druggable subpockets of the A2A adenosine receptor binding site 202
Identification of alpha(1)-adrenoceptor subtypes involved in contraction of young CD rat epididymal vas deferens 201
2-phenylhydroxypropynyladenosine derivatives as high potent agonists at A(2B) adenosine receptor subtype 200
2-substituted 5 '-N-methylcarboxamidoadenosine (MECA) derivatives as A(3) adenosine receptor ligands 199
Frontal affinity chromatography-mass spectrometry useful for characterization of new ligands for GPR17 receptor. 198
Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases 198
Ring opening reactions: synthesis of AICAR analogs as potential antimetabolite agents 197
Simulation and comparative analysis of binding modes of nucleoside and non-nucleoside agonists at the A2B adenosine receptor 197
New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile 196
The importance of alkynyl chain presence for the activity of adenine nucleosides/nucleotides on purinergic receptors 196
The aminopyridine-3,5-dicarbonitrile core for the design of new non-nucleoside-like agonists of the human adenosine A2B receptor 196
Pharmacological postconditioning of the rabbit heart with non-selective, A1, A2A and A3 adenosine receptor agonists 195
Innovative functional cAMP assay: application to the pharmacological characterization of GPR17 193
A3 Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity 191
The Chemistry and Occurrence of Taxane Derivatives. XXVI. A Reactivity Study on 11(15→1)Abeotaxanes 190
Solid phase synthesis and antiprotozoal evaluation of di- and trisubstituted 5 '-carboxamidoadenosine analogues 190
GPCRs as therapeutic targets: a view on adenosine receptors structure and functions, and molecular modeling support 189
Evaluation of adenine as scaffold for the development of novel P2X3 receptor antagonists 189
[3H]HEMADO – a novel tritiated agonist selective for the human adenosine A(3) receptor 185
Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors 185
Introduction of alkynyl chains on C-8 of adenosine led to very selective antagonists of the A(3) adenosine receptor 184
A(2B) adenosine receptor agonists: synthesis and biological evaluation of 2-phenylhydroxypropynyladenosine and NECA derivatives 182
9-Ethyladenine derivatives as adenosine receptor antagonists: 2- and 8-substitution result in distinct selectivities. 181
A2A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable? 181
Human adenosine A3 receptor as selective target of new 2-aralkynyl-N6-methyl-MECA derivatives 180
Purine nucleosides bearing 1-alkynyl chains as adenosine receptor agonists 177
Coupling of 2,6-disubstituted purines to ribose-modified sugars 176
Adenosine Receptors as Neuroinflammation Modulators: Role of A1 Agonists and A2A Antagonists 176
Synthesis, structure-affinity relationships and molecular modeling studies of novel pyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists 175
Synthesis and adenosine receptor affinity and potency of 8-alkynyl derivatives of adenosine 175
Synthesis and stability studies of 2 ',3 ',5 '-tri-O-acetyl-2-amino(-N-6-cyclopentyl)-1-deazaadenosines 174
Pyrazolo[1,5-c]quinazoline derivatives and their simplified analogues as adenosine receptor antagonists. Synthesis, structure-affinity relationships and molecular modeling studies 174
Effects of 5 '-phosphate derivatives of 2-hexynyl adenosine and 2-phenylethynyl adenosine on responses of human platelets mediated by P2Y receptors 171
Functional cAMP assay optimization at CHO cells expressing A2A adenosine receptors and stably transfected with firefly luciferase biosensor 168
N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands 167
A2A Adenosine Receptor Antagonists and their Potential in Neurological Disorders 165
Probing ambiguous base-pairs by genetic transformation with XNA templates 163
Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease 163
Purinergic P2X receptors: Structural models and analysis of receptor-ligand interaction 161
Adenosine receptor agonists:synthesis and binding affinity of 2-(aryl)alkylthioadenosine derivatives 157
Highlights on the development of A(2A) adenosine receptor agonists and antagonists 157
Synthesis of new nucleosides by coupling of chloropurines with 2- and 3-deoxy derivatives of N-methyl-D-ribofuranuronamide 154
N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A(3) adenosine receptor 152
Synthesis and biological activity of trisubstituted adenines as A(2A) adenosine receptor antagonists 151
New potent and selective A1 adenosine receptor antagonists as potential tools for the treatment of gastrointestinal diseases 149
Substituted adenine derivatives as novel P2X3 receptor ligands 148
New purine derivatives as P2X3 receptor antagonists 145
Totale 22.039
Salva come PNG Salva come JPEG
Categoria #
all - tutte 106.509
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 106.509
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021850 0 0 0 0 0 0 0 0 0 155 439 256
2021/20221.648 185 417 34 40 77 81 94 127 125 176 114 178
2022/20231.815 203 122 46 308 177 259 9 106 316 105 111 53
2023/20241.412 190 79 95 63 66 127 55 91 163 38 42 403
2024/20254.798 191 112 389 227 181 291 574 1.190 391 295 307 650
2025/20266.077 426 374 693 956 775 514 1.105 496 410 328 0 0
Totale 27.065